Ramzi Haddadin, MD
Pulmonary Disease · Beckley, WVNPI 1902844848
Payments from drug & device makers
Across 498 payments — averaging $86.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$37K
- GSK$1K
- Regeneron Healthcare Solutions, Inc.$472
- Amgen$428
- Takeda Pharmaceuticals U.S.A., Inc.$388
- Boehringer Ingelheim$385
- plus $3K from 28 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 197 | $37,101 |
| GSK | 90 | $1,405 |
| Regeneron Healthcare Solutions, Inc. | 34 | $472 |
| Amgen | 22 | $428 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $388 |
| Boehringer Ingelheim | 23 | $385 |
| Mylan Specialty L.p. | 18 | $358 |
| Sanofi | 10 | $331 |
| Sunovion Pharmaceuticals Inc. | 15 | $266 |
| Grifols USA, LLC | 7 | $225 |
| Shire North American Group Inc | 7 | $154 |
| Verona Pharma, Inc. | 4 | $152 |
| Inspire Medical Systems, Inc. | 5 | $141 |
| Mallinckrodt Hospital Products Inc. | 2 | $119 |
| Baxter Healthcare | 5 | $105 |
| Actelion Pharmaceuticals US, Inc. | 5 | $98 |
| Pulmonx Corporation | 4 | $98 |
| Insmed, Inc. | 6 | $97 |
| United Therapeutics Corporation | 1 | $79 |
| Genentech USA, Inc. | 4 | $73 |
| Circassia Inc. | 4 | $67 |
| Pfizer | 3 | $58 |
| Sanofi-aventis U.S. LLC | 1 | $41 |
| Bayer | 2 | $41 |
| Teva Pharmaceuticals USA, Inc. | 3 | $40 |
| AbbVie | 2 | $33 |
| Electromed, Inc. | 1 | $22 |
| La Jolla Pharmaceutical Company | 1 | $20 |
| Ambu Inc. | 1 | $20 |
| Inogen, Inc. | 1 | $19 |
| Vifor Pharma, Inc. | 1 | $17 |
| Seqirus USA Inc | 1 | $14 |
| Advanced Respiratory, Inc | 1 | $13 |
| Breathe Technologies, Inc. | 1 | $13 |
How this compares
$42,892 in reported general payments places this provider in the 90th percentile of 89 pulmonary disease providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Beckley
- Maria BoustaniBeckley$663K
- Charles PorterfieldBeckley$8K
- Shirkant BembalkarBeckley$746
- William PowersBeckley$589
- Loay Al AsadiCharleston$461K
- Melvin SaludesGlen Dale$255K
- Amro Al-AstalHuntington$231K
- Roger AbrahamsMorgantown$177K
- Houssein YounessMartinsburg$31K
- Salam RajjoubBridgeport$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.